Liquidia (LQDA) Q1 2026 Earnings Transcript

Liquidia reported Q1 2026 net product sales of $129.9 million, up 44% sequentially from $90.1 million, with net income rising to $52.9 million and adjusted EBITDA increasing to $71.2 million. YUTREPIA prescriptions reached about 4,500 unique patient scripts since launch, market share in inhaled prostacyclins climbed to nearly 23%, and management said the annualized revenue run rate exceeded $500 million with a clear line of sight to $1 billion in 2027. The company also initiated new studies and is funding commercial, clinical, and manufacturing expansion from operating cash flow, while acknowledging ongoing income tax expense due to profitability.

Analysis

LQDA’s print is less about a single-quarter revenue beat than evidence of a rapid category capture dynamic: once a few high-volume prescribers get comfortable, the drug appears to move from trial status to default status. That matters because inhaled prostacyclin is a referral-network business, not a pure demand-creation business; increasing depth at existing centers should lower future CAC and make the commercial model more self-funding than peers expect.

The second-order implication is that management is using profitability to de-risk a much broader platform story before the market has fully priced it. If operating cash flow is already financing sales expansion, manufacturing buildout, and multiple studies, equity dilution risk drops materially, which should compress the stock’s “biotech financing discount.” The flip side is that the current narrative is now tightly linked to continued conversion in PH-ILD and switching momentum from older prostacyclin modalities; any plateau in prescriber depth would hit valuation harder than a small miss on quarterly sales.

The most interesting competitive read-through is to UTHR and the broader prostacyclin stack: LQDA is not just taking share, it may be changing the treatment algorithm by pulling patients earlier and from higher-friction delivery systems. That creates a potential loser set that includes pump- and oral-based prostacyclin strategies, while also expanding the addressable market through better diagnosis and referral behavior. The contrarian risk is that the market may be extrapolating linear share gains into a large fraction of the total prostacyclin universe; the next inflection will likely depend on whether new centers and community prescribers keep expanding at the same pace over the next 2-3 quarters, not whether Q1 itself was strong.

Key Decisions for Investors

• Go long LQDA on a 3-6 month horizon; best entry is on any post-earnings consolidation rather than strength-chasing. Risk/reward is attractive if the market continues to price in cash-funded growth and multiple indication optionality; downside is a sharp derating if prescription depth flattens.
• Pair trade: long LQDA / short UTHR for 1-2 quarters. Thesis: LQDA is gaining share at the margin in the inhaled prostacyclin category while UTHR is the structural incumbent facing increasing switching pressure; hedge general pulmonary market beta.
• Buy LQDA call spreads 6-12 months out to express continuation of the growth narrative with defined risk. This is cleaner than stock if you expect momentum but want to limit exposure to litigation or trial-timing volatility.
• Use LQDA strength to short dated volatility around litigation/trial headlines only if implied vol spikes materially above realized; the equity now has multiple catalysts, so naked shorting is poor risk/reward unless there is evidence of prescription deceleration.
• Watch for a reversal trigger: two consecutive months of slower new prescriber adds or weaker center-to-community mix. If that appears, reduce longs aggressively because the valuation is now dependent on sustained adoption velocity, not just installed-base monetization.